Biogen Idec is no longer for sale
Stock plunges after drug maker reports no definitive offers
Biogen Idec Inc. is taking down the "for sale" sign. The Cambridge biotechnology company yesterday said it has decided to remain independent, after failing to receive a single offer to buy the company. But it wasn't for lack of trying - over the past two months, Biogen Idec said, it had contacted every major drug company to see if any ... (Full article: 782 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
